Skip to content
Catalyst

N-hexadecanoylethanolamineFinding

N-hexadecanoylethanolamine increases brain-derived neurotrophic factor (BDNF) concentration

raisesLimited evidenceFinding

01 · The sentence it was drawn from

“Following six weeks of supplementation with Levagen+® PEA, the expression of serum BDNF significantly increased by 2.76 ± 6.12 ng/mL (p = 0.0005) compared with no change in the placebo (−0.72 ± 7.16 ng/mL; p = 0.39).”
Quoted verbatim from Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial.
This finding among the 2 findings on its endpoint

N-hexadecanoylethanolamine

Brain-derived neurotrophic factor (BDNF) concentration

raises

Who
n = 39 · Healthy young university students in London, randomised double-blind placebo-controlled crossover, 6-week arms with 6-week washout; placebo was microcrystalline cellulose capsules
Dose studied
Levagen+ (formulated PEA), 2 capsules daily, 600 mg PEA total daily dose, oral, 6 weeks

Limited evidencePMID 38398813 · 2024

02 · The study

Study
crossover
Participants
39
Duration
6 weeks

Evidence, by strength

  • strong
  • moderate
  • limitedthis finding
  • very limited
  • insufficient

03 · The paper

Nutrients
What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M70G34HP0E627H206JQQ8CZ9